Ucci-Hn-17-02 An Open-Label, Phase II Study Of Durvalumab (Medi4736) In Combination With Cetuximab In Previously Treated Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (Hnscc)
Posted Date: May 20, 2019
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to determine the objective response rate of the combination of Durvalumab and Cetuximab using RECIST 1.1 in subjects with recurrent and/or metastatic HNSCC who have progressed following platinum therapy.
Criteria:
To Be Eligible: Age 18 Or Older, Bodyweight >30Kg, Must Have Recurrent Or Metastatic Hnscc, No Other Malignancy Within 5 Years
Keywords:
Head And Neck Cancer, Recurrent, Metastatic
For More Information:
Uccc Clinical Trials Office
513-584-7698
cancer@uchealth.com